see also Lung cancer intracranial metastases treatment.

Lung cancer metastases treatment involves a comprehensive and personalized approach that considers the type of primary cancer, the extent and location of metastases, the patient's overall health, and the treatment goals. Metastatic lung cancer can arise from various primary cancers, such as breast, colon, kidney, and more. The treatment options can include:

1. Systemic Therapy:

Chemotherapy: Certain chemotherapy drugs can target rapidly dividing cancer cells throughout the body. Chemotherapy is often used in cases of widespread metastatic disease. Targeted Therapy: If the metastatic cancer has specific genetic mutations or alterations, targeted therapies that inhibit these mutations can be used. Examples include EGFR inhibitors for EGFR-mutated lung cancer. Immunotherapy: Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, can help the immune system recognize and attack cancer cells. They have shown promising results in various types of metastatic lung cancer.

2. Localized Treatments:

Surgery: In cases where a limited number of metastases are present and are surgically accessible, surgical removal (metastasectomy) might be considered. This is more common in cases where the primary cancer is well-controlled.

Radiotherapy: Stereotactic Body Radiotherapy (SBRT) or rSBRT, can deliver precise and localized radiation to the metastatic sites. This approach is suitable for patients with a limited number of metastases, especially when surgery is not feasible.

3. Palliative Care: Palliative care focuses on improving the patient's quality of life by managing symptoms, such as pain and shortness of breath, associated with advanced cancer. This approach is important even in cases of metastatic disease.

4. Clinical Trials: Participation in clinical trials can provide access to cutting-edge treatments and therapies that are still in the experimental stage. Clinical trials help advance medical knowledge and may offer potential benefits to patients with metastatic lung cancer.

5. Multidisciplinary Care: The treatment of metastatic lung cancer often involves a team of medical oncologists, radiation oncologists, surgeons, radiologists, and other specialists who collaborate to determine the best treatment strategy for each patient.

It's crucial to note that the treatment approach for lung cancer metastases is highly individualized, and the choice of treatment depends on factors such as the patient's overall health, the location and number of metastases, and the characteristics of the primary cancer. Patients should have open discussions with their healthcare team to understand the potential benefits, risks, and expected outcomes of the various treatment options available to them.

Radiotherapy plays a significant role in the treatment of lung cancer metastases, particularly when surgery or systemic treatments are not feasible or when localized control of the metastatic lesions is desired. Different radiotherapy techniques can be used based on the characteristics of the metastases, the patient's overall health, and treatment goals. Here's an overview of radiotherapy options for lung cancer metastases:

1. External Beam Radiotherapy (EBRT):

Conventional Fractionation: In cases of multiple lung metastases, conventional EBRT delivers radiation over multiple treatment sessions (fractions) to provide palliative relief, control tumor growth, and alleviate symptoms. Stereotactic Body Radiotherapy (SBRT): SBRT, also known as stereotactic ablative radiotherapy (SABR), involves delivering high doses of radiation in a few sessions to precisely target small metastases. It's highly effective due to its ability to spare healthy tissue while focusing on the tumor. 2. Image-Guided Radiotherapy (IGRT): IGRT employs real-time imaging during treatment to accurately target the metastatic lesions, accounting for any changes in tumor position due to breathing or other movements. This technique enhances the precision of radiation delivery.

3. Intensity-Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT): These advanced techniques allow for the modulation of radiation intensity and the shape of the treatment beams, enabling better conformity to the tumor shape while minimizing radiation exposure to surrounding healthy tissues.

4. Proton Therapy: Proton therapy is a specialized form of radiotherapy that uses protons instead of conventional X-rays. It can provide targeted radiation to the tumor while reducing the dose to nearby healthy tissues. This approach is particularly useful for metastases near critical structures.

5. Palliative Radiotherapy: For patients with metastatic lung cancer experiencing symptoms like pain, shortness of breath, or bleeding, palliative radiotherapy can help alleviate these symptoms and improve quality of life by targeting specific areas causing discomfort.

6. Combination Therapies: Radiation therapy can be combined with systemic treatments such as chemotherapy or immunotherapy to enhance the overall effectiveness of treatment and potentially increase survival rates.

7. Treatment Planning and Individualization: Radiation therapy for lung cancer metastases involves careful treatment planning, considering factors like the size and location of the metastases, the primary cancer type, the patient's medical history, and previous treatments. Treatment plans are individualized to optimize both tumor control and patient well-being.

It's important for patients with lung cancer metastases to discuss their treatment options with a multidisciplinary team of medical oncologists, radiation oncologists, and other specialists. Each patient's case is unique, and the choice of radiotherapy technique should be made based on a comprehensive assessment of the patient's condition and treatment goals.

• Delayed Abscopal Response 3 Years After Robotic Stereotactic Body Radiation Therapy for Renal Cell Carcinoma: A Case Report
• Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs
• Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial
• Low-Burden Oligometastatic Disease of the Lung Treated with Robotic Stereotactic Ablative Radiotherapy: A Retrospective Study
• Dynamics of VEGF-, ngiopoietin-2 and HIF-1alpha Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery
• Evaluation of the Effect of Radiosurgery for Target and Non-Target Lesions in Patients with Brain Metastases Using RANO-BM Criteria
• Robotic stereotactic radiosurgery with CyberKnife - brain metastases and fibrinolysis
• CyberKnife() stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study

Robotic Stereotactic Body Radiotherapy (rSBRT) is a specialized and precise treatment option for lung cancer metastases that combines advanced robotics, stereotactic principles, and accurate imaging to deliver high doses of radiation to metastatic lesions while minimizing damage to surrounding healthy tissues. Here's a more detailed exploration of rSBRT for lung cancer metastases:

1. Precision and Accuracy: Robotic systems, such as the Accuray CyberKnife®, are employed to precisely position the radiation beams from various angles, adjusting for any patient movement or tumor shifts during treatment. This level of accuracy allows for extremely focused radiation delivery, increasing the likelihood of effectively targeting metastatic lesions.

2. Imaging Integration: rSBRT relies on real-time imaging, often including CT scans and sometimes cone-beam CT, to track the position of the tumor and adjust the radiation beams accordingly. This ensures that the radiation is delivered to the exact location of the metastases, accounting for any breathing or other organ movement.

3. Treatment Planning: Before treatment, a detailed plan is created based on imaging data. The goal is to deliver a high radiation dose to the tumor while minimizing exposure to healthy tissues. The radiation oncology team determines the optimal number of treatment sessions (fractions) and radiation doses to achieve maximum tumor control.

4. Hypofractionation: rSBRT typically employs a hypofractionated approach, delivering a higher dose of radiation in a smaller number of treatment sessions. This capitalizes on the radiobiological principle that fewer, larger radiation doses can be more effective in damaging tumor cells while allowing healthy tissues to recover.

5. Patient Comfort: Due to its non-invasive nature and the precision of the robotic system, rSBRT offers patients a relatively comfortable experience. In some cases, patients might not require anesthesia, and the treatments are typically completed within a shorter timeframe compared to traditional radiotherapy.

6. Applicability to Lung Metastases: rSBRT is particularly suitable for treating lung metastases due to the lung's ability to tolerate higher doses of radiation within small, well-defined treatment areas. It is often employed when surgery is not an option or when patients prefer a non-invasive treatment approach.

7. Efficacy and Outcomes: Studies have shown that rSBRT can achieve excellent local control rates for lung metastases, often comparable to surgical removal. The high precision and focused radiation delivery contribute to effective tumor eradication.

8. Multidisciplinary Approach: Like all cancer treatments, rSBRT is most effective when integrated into a comprehensive treatment plan that considers the patient's overall health, the characteristics of the metastases, and any other ongoing treatments.

9. Side Effects: While rSBRT is generally well-tolerated, there can be side effects, including temporary inflammation of lung tissue (pneumonitis). The risk and severity of side effects depend on factors like the dose of radiation, the location of the metastases, and the patient's individual health.

In summary, Robotic Stereotactic Body Radiotherapy (rSBRT) is a powerful and precise treatment option for lung cancer metastases. It offers patients a focused and non-invasive approach that can lead to effective tumor control while minimizing damage to surrounding tissues. Patients considering rSBRT should discuss their options with their oncology team to determine the best treatment plan for their specific case.

Rosenbrock et al. presented a retrospective analysis focused on the effectiveness and safety of robotic stereotactic body radiotherapy (rSBRT) for treating lung cancer metastases in patients with oligometastatic disease.

1. Research Context and Objectives: The abstract provides a clear overview of the research's context by explaining the significance of rSBRT in treating lung metastases among patients with oligometastatic disease. The objective is well-defined: to assess the local control rate, progression-free survival, overall survival, and toxicity associated with rSBRT, while identifying independent factors influencing its efficacy and safety.

2. Patient Cohort and Methodology: The methodology mentions a retrospective single-center analysis of patients with various cancer types who underwent rSBRT using the Accuray Cyberknife® device. This description provides an understanding of the patient demographics and the treatment modality used, which enhances the study's credibility. The temporal scope (2012-2019) and the inclusion of different cancer types emphasize the study's generalizability.

3. Treatment Outcomes: The abstract presents essential treatment outcomes, such as the 4-year Kaplan-Meier estimates for local control rate (LC), progression-free survival (PFS), and overall survival (OS). These metrics provide insights into the effectiveness of rSBRT in managing lung metastases. The reported LC of 72.0% suggests favorable tumor control, while the lower PFS (12.4%) and OS (49.7%) indicate challenges in preventing disease progression and achieving long-term survival, which is common in metastatic settings.

4. Factors Influencing Treatment Efficacy: The study conducts a Cox regression analysis to identify independent factors affecting the efficacy of rSBRT. Notably, it finds that LC for metastases from colorectal carcinoma and those treated with a lower biological effective dose (BED10) is significantly worse. This finding underscores the importance of tailoring treatment parameters based on tumor histology and radiation dose to optimize outcomes.

5. Safety and Toxicity: The abstract mentions the occurrence of grade I-II pneumonitis in 21.4% of cases treated with rSBRT. This information highlights the potential toxicity associated with the treatment, which is crucial for evaluating the overall risk-benefit profile of rSBRT.

6. Conclusion: The study concludes that rSBRT is an effective and safe therapy for lung metastases, aligning with the initial hypothesis. It also suggests that aiming for a higher BED10 (>100 Gy) is advisable, particularly for radioresistant histologies such as colorectal carcinoma, to improve treatment outcomes.

7. Limitations and Future Directions: While the abstract provides valuable insights, it's important to acknowledge potential limitations. Being a retrospective study from a single center, there might be inherent biases and generalizability concerns. Additionally, the abstract doesn't elaborate on the specific clinical and treatment-related characteristics of patients, which could provide a deeper understanding of the results.

In conclusion, this abstract contributes valuable information to the field of rSBRT for lung metastases in patients with oligometastatic disease. The study's findings, particularly regarding factors influencing efficacy and the importance of radiation dose, can guide future research and clinical decision-making ¹⁾.

Berkovic et al. report treatment efficacy and toxicity of patients treated by robotic (Cyberknife®) stereotactic body radiotherapy (SBRT) for oligorecurrent lung metastases (ORLM). 1. Clear Research Objective: The study's primary goal of evaluating the treatment outcomes and toxicity of patients undergoing robotic SBRT for ORLM is well-defined. The study seeks to provide valuable insights into the effectiveness and safety of this treatment approach.

2. Study Design and Patient Cohort: The study design is well-structured, involving consecutive patients with confirmed ORLM. The inclusion of patients with various primary cancer sites enhances the study's generalizability. The use of CyberKnife® robotic technology for SBRT adds to the novelty and relevance of the research.

3. Treatment Efficacy Findings: The study's findings demonstrate promising treatment efficacy. The reported 1-, 2-, and 3-year local control rates, lung progression-free survival, distant progression-free survival, and overall survival rates provide a comprehensive overview of the treatment outcomes for ORLM patients. These rates offer insights into both short- and long-term responses to SBRT.

4. Impact of Variables: The study examines the influence of various tumor, patient, and treatment-related parameters on outcomes. Identifying variables that significantly impact local control, lung progression-free survival, and overall survival provides valuable information for treatment optimization and patient selection.

5. Multivariable Analysis: The utilization of multivariable analysis allows for the identification of independent factors that influence outcomes. The consideration of factors like tumor volume, dose coverage, and primary tumor site helps in understanding the nuances that contribute to treatment success.

6. Toxicity Assessment: The study provides an important assessment of treatment-related toxicity, including acute and late radiation pneumonitis. The inclusion of this information is crucial for understanding the balance between treatment benefits and potential risks.

7. Implications for Clinical Practice: The study's conclusion, indicating that SBRT is highly effective and could achieve long-term survival for patients with favorable prognostic features, has potential implications for clinical practice. This information can guide treatment decisions and discussions with patients.

8. Limitations and Future Directions: While the study provides valuable insights, it's important to acknowledge any limitations, such as the retrospective nature of the analysis and the relatively small sample size. Future research could involve larger cohorts and potentially include subgroup analyses based on primary tumor sites and other variables.

In summary, the study contributes significant insights into the treatment landscape of oligorecurrent lung metastases using robotic SBRT. Its findings offer a foundation for further research and discussions within the medical community regarding the role of SBRT in managing metastatic lung cancer. The study's comprehensive evaluation of treatment outcomes, toxicity, and influencing variables strengthens its contribution to the field. ²⁾